Invention Grant
US08741835B2 Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
有权
使用生长素释放肽激动剂来改善糖皮质激素治疗的分解代谢作用
- Patent Title: Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
- Patent Title (中): 使用生长素释放肽激动剂来改善糖皮质激素治疗的分解代谢作用
-
Application No.: US13287211Application Date: 2011-11-02
-
Publication No.: US08741835B2Publication Date: 2014-06-03
- Inventor: Giovanni Tulipano , Andrea Giustina , Zheng Xin Dong , Michael DeWitt Culler
- Applicant: Giovanni Tulipano , Andrea Giustina , Zheng Xin Dong , Michael DeWitt Culler
- Applicant Address: FR Boulogne
- Assignee: Ipsen Pharma S.A.S.
- Current Assignee: Ipsen Pharma S.A.S.
- Current Assignee Address: FR Boulogne
- Agent Janice Klunder
- Main IPC: A61K38/08
- IPC: A61K38/08
Abstract:
A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 (SEQ ID NO:73) or other suitable ghrelin agonist, to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.
Public/Granted literature
- US20120129767A1 USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT Public/Granted day:2012-05-24
Information query
IPC分类:
